<SEC-DOCUMENT>0001193125-25-320166.txt : 20251216
<SEC-HEADER>0001193125-25-320166.hdr.sgml : 20251216
<ACCEPTANCE-DATETIME>20251216101720
ACCESSION NUMBER:		0001193125-25-320166
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20251216
DATE AS OF CHANGE:		20251216

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STAAR SURGICAL CO
		CENTRAL INDEX KEY:			0000718937
		STANDARD INDUSTRIAL CLASSIFICATION:	OPHTHALMIC GOODS [3851]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				953797439
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1227

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-11634
		FILM NUMBER:		251573666

	BUSINESS ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016
		BUSINESS PHONE:		6263037902

	MAIL ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STAAR SURGICAL COMPANY
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>d76484ddefa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML><HEAD>
<TITLE>DEFA14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549</B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROXY
STATEMENT PURSUANT TO SECTION 14(A) OF THE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the Registrant&#8194;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by a Party other
than the Registrant&#8194;&#9744; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preliminary Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidential, for Use of the Commission Only (as permitted by Rule
<FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT> </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Additional Materials </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting Material under <FONT STYLE="white-space:nowrap">&#167;240.14a-12</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>STAAR SURGICAL COMPANY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified In Its Charter) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No fee required. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee paid previously with preliminary materials. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules
<FONT STYLE="white-space:nowrap">14a-6(i)(1)</FONT> and <FONT STYLE="white-space:nowrap">0-11</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>On December&nbsp;16, 2025, STAAR Surgical Company (&#8220;STAAR&#8221; or the &#8220;Company&#8221;)
issued the following press release: </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g76484g1216054901767.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Independent Industry Analysts Recognize Value Provided to STAAR Stockholders by Amended Alcon Merger
Agreement and Merits of Alcon Transaction </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Increased Alcon Merger Price of $30.75 per Share is an Attractive Outcome for STAAR
Stockholders</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LAKE FOREST, Calif. &#8212; December&nbsp;16, 2025 &#8212; STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with
the EVO family of Implantable Collamer<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Lenses (EVO ICL<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>) for vision correction, today reported that independent industry analysts
have recognized the value provided to STAAR stockholders by the Company&#8217;s amended merger agreement with Alcon (SIX/NYSE: ALC) and the merits of the Alcon transaction. The Alcon merger agreement, as revised on December&nbsp;9, 2025, provides
that STAAR stockholders will receive $30.75 per share in cash if the transaction with Alcon is consummated, representing a 74% premium to STAAR&#8217;s <FONT STYLE="white-space:nowrap">90-day</FONT> Volume Weighed Average Price as of August&nbsp;4,
2025 and a 66% premium to the closing price of STAAR common stock on August&nbsp;4, 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Independent industry analysts have stated: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;We think STAA shareholders should take this offer otherwise STAA shares are likely to meaningfully suffer
if the deal is not consummated.&#8221; (BTIG, Dec.&nbsp;9, 2025) </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;ALC increases acquisition price following expiration of the
<FONT STYLE="white-space:nowrap">go-shop</FONT> period &#133; Given the announcement earlier this week of the expiration of the <FONT STYLE="white-space:nowrap">&#8220;go-shop&#8221;</FONT> process, where no other proposals materialized and there
was seemingly limited interest by others in acquiring STAA (evident by the few number of NDAs that were signed), we believe that these changes will likely satisfy shareholders.&#8221; (Canaccord Genuity, Dec. 9, 2025) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;Healthy premium remains, <FONT STYLE="white-space:nowrap">go-shop</FONT> complete. The $1.6bn <FONT
STYLE="white-space:nowrap">all-in</FONT> takeout valuation prices the transaction at roughly ~4.5x on a forward EV/Sales basis using our blended 2026-2027 prevailing STAA estimates ($271mn in 2026; $300mn in 2027). This approximate ~4.5x exit
multiple is comparable to smid-cap growth peers with a topline growth profile of 10%+ which trade in the 4x to 6x range on &#8216;26/&#8216;27 estimates. The proposed offer is also <FONT STYLE="white-space:nowrap">in-line</FONT> with recent deals
across the US Medtech space&#133; Hence, we see the ~4.5x proposed exit multiple as sufficiently fair.&#8221; (Mizuho, Dec. 9, 2025) </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;The new offer represents an attractive outcome for shareholders, in our view, particularly given the
absence of a competing bid following the second <FONT STYLE="white-space:nowrap">go-shop</FONT> period.&#8221; (Needham, Dec. 9, 2025) </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, as announced yesterday, independent proxy advisory firm Institutional Shareholder Services (&#8220;ISS&#8221;) has issued an updated report and
now recommends that STAAR stockholders vote &#8220;FOR&#8221; the Alcon transaction. In its report, ISS states that &#8220;uncertainties about valuation are now outweighed by the combination of more acute downside risks and improved terms&#8221;<SUP
STYLE="font-size:75%; vertical-align:top">1</SUP> with respect to the Alcon agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The STAAR Board of Directors recommends that stockholders vote
&#8220;FOR&#8221; the Alcon merger on the WHITE proxy card TODAY to protect the value of their investment. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>STAAR will hold a virtual Special
Meeting of Stockholders on December&nbsp;19, 2025, at 8:30 a.m. (Pacific Time). Stockholders of record as of the close of business on October&nbsp;24, 2025, are entitled to vote at the meeting. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholders with questions about voting their shares should contact STAAR&#8217;s proxy solicitor, Innisfree M&amp;A Incorporated: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For stockholders: +1 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">877-750-8233</FONT></FONT>
(toll-free from the U.S. and Canada) or +1 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">412-232-3651</FONT></FONT> (from other countries) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For banks and brokerage firms: +1
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">212-750-5833</FONT></FONT> </P></TD></TR></TABLE><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Permission to use quotations here and throughout neither sought nor obtained </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About STAAR Surgical </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need
for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICLs are clinically-proven to deliver safe long-term vision correction without removing corneal tissue or the
eye&#8217;s natural crystalline lens. Its EVO ICL<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> product line provides visual freedom through a quick, minimally invasive procedure. STAAR has sold more than 3&nbsp;million ICLs in over 75
countries. Headquartered in Lake Forest, California, the company operates research, development, manufacturing, and packaging facilities in California and Switzerland. For more information about ICL, visit www.EVOICL.com. To learn more about STAAR,
visit www.staar.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Information About the Merger and Where to Find It </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication relates to the proposed transaction involving STAAR. In connection with the proposed transaction, STAAR has filed relevant materials with
the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;), including STAAR&#8217;s definitive proxy statement on Schedule 14A (the &#8220;Proxy Statement&#8221;), on September&nbsp;16, 2025. The Proxy Statement was first sent to STAAR
stockholders on September&nbsp;16, 2025, and was thereafter supplemented. This communication is not a substitute for the Proxy Statement or any other document that STAAR may file with the SEC or send to its stockholders in connection with the
proposed transaction. BEFORE MAKING ANY VOTING DECISION, STOCKHOLDERS OF STAAR ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC, INCLUDING THE PROXY STATEMENT, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS THERETO, IN CONNECTION
WITH THE PROPOSED TRANSACTION WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain the documents (when available) free of charge at the
SEC&#8217;s website, www.sec.gov, or by visiting STAAR&#8217;s investor relations website, https://investors.staar.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Offer or Solicitation
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication is for informational purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the
solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise,
nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participants in the Solicitation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under SEC rules, STAAR and certain of its directors, executive officers and other members of management and employees may be deemed to be participants in the
solicitation of proxies from the holders of STAAR&#8217;s common stock in connection with the proposed transaction. Information about the directors and executive officers of STAAR and their ownership of STAAR&#8217;s common stock is set forth in the
Proxy Statement, the definitive proxy statement for STAAR&#8217;s 2025 Annual Meeting of Stockholders (the &#8220;Annual Proxy Statement&#8221;), which was filed with the SEC on April&nbsp;24, 2025 (and which is available
at&nbsp;https://www.sec.gov/ix?doc=/Archives/edgar/data/0000718937/000095017025058174/staa-20250424.htm), including the sections captioned &#8220;Compensation of Directors,&#8221; &#8220;Information Regarding Executive Officers&#8221; and
&#8220;Security Ownership of Principal Shareholders and Management,&#8221; or its Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;27, 2024, which was filed with the SEC on February&nbsp;21, 2025
(and which is available at&nbsp;https://www.sec.gov/ix?doc=/Archives/edgar/data/0000718937/000095017025024813/staa-20241227.htm), and in other documents filed by STAAR with the SEC. To the extent holdings of such participants in STAAR&#8217;s
securities have changed since the amounts described in the Proxy Statement, such changes have been reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC by STAAR&#8217;s
directors and executive officers. These documents can be obtained free of charge from the sources indicated above. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests,
by security holdings or otherwise, will be contained in other relevant materials to be filed with the SEC in respect of the proposed transaction when they become available. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information covered by
this communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often contain words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221;
&#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;continue,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;may,&#8221; and similar terms. All statements in this communication that are not
statements of historical fact are forward-looking statements. These forward-looking statements are neither promises nor guarantees and involve known and unknown risks, uncertainties and other important factors that may cause actual results,
performance or achievements to be materially different from what is expressed or implied by the forward-looking statements, including, but not limited to: (1)&nbsp;the occurrence of any event, change or other circumstances that could give rise to
the termination of the Alcon merger agreement or could cause the consummation of the proposed transaction to be delayed or to fail to occur; (2)&nbsp;the failure to obtain approval of the proposed transaction from STAAR&#8217;s stockholders;
(3)&nbsp;the failure to obtain certain required regulatory approvals or the failure to satisfy any of the other closing conditions to the completion of the proposed transaction within the expected timeframes or at all; (4)&nbsp;risks related to
disruption of management&#8217;s attention from STAAR&#8217;s ongoing business operations due to the proposed transaction; (5)&nbsp;the effect of the announcement of the proposed transaction on the ability
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of STAAR to retain and hire key personnel and maintain relationships with its customers, suppliers and others with whom it does business, or on its operating results and business generally;
(6)&nbsp;the ability of STAAR to meet expectations regarding the timing and completion of the transaction; (7)&nbsp;the outcome of any legal proceedings that may be instituted against STAAR related to the proposed transaction; (8)&nbsp;the
possibility that STAAR&#8217;s stock price may decline significantly if the proposed transaction is not consummated; and (9)&nbsp;other important factors set forth in the Proxy Statement under the caption &#8220;Risk Factors&#8221; and STAAR&#8217;s
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;27, 2024 under the caption &#8220;Risk Factors,&#8221; as any such factors may be updated from time to time in STAAR&#8217;s other filings with the
SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forward-looking statements speak only as of the date they are made and, except as may be required under applicable law, STAAR undertakes no
obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>STAAR Contacts:
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Niko Liu, CFA </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States: +1 <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">626-303-7902</FONT></FONT> (ext 3023) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hong Kong:
<FONT STYLE="white-space:nowrap">+852-6092-5076</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">nliu@staar.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">investorrelations@staar.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Connie Johnson </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">626-303-7902</FONT></FONT> (ext 2207) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">cjohnson@staar.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lucas Pers / Alexandra Benedict </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Joele Frank, Wilkinson Brimmer Katcher </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">212-895-8692</FONT></FONT> / +1 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">212-895-8644</FONT></FONT> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g76484g1216054901767.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g76484g1216054901767.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] 2L# 2(  A$! Q$!_\0
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MT,OPPTB-6VE[5E!],EJK_#K4K6U\-Q:%<R);ZEIK/#<0R$*Q.XG<,]00<YH
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1S1F@!:*3-&: %HI,T9H _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
